DYNAVAX TECHNOLOGIES CORPDVAX财报
Nasdaq · 医疗保健 · 药物制剂
Dynavax Technologies Corp是一家处于商业化阶段的生物制药企业，专注于研发和生产针对传染病的创新疫苗及免疫疗法，核心上市产品为成人乙肝疫苗Heplisav-B，主要市场覆盖北美与欧洲，同时拥有多款针对未满足公共卫生需求的在研产品。
主要股东
| 股东 | 持股比例 | 股数 | 变动 | 截至 |
|---|---|---|---|---|
| BlackRock, Inc. | 16.00% | 21.0M | 无变化 | 2024-11-12 |
| Deep Track Biotechnology Master Fund, Ltd. | 13.60% | 17.8M | ▲ +4.04pp | 2024-10-24 |
| The Vanguard Group | 7.18% | 9.3M | — | 2024-02-13 |
| Kynam Capital Management, LP | 6.34% | 8.3M | — | 2024-11-14 |
| STATE STREET CORPORATION | 5.90% | 7.7M | ▼ -1.45pp | 2024-10-16 |
| Deep Track Capital, LP | 5.49% | 7.1M | ▲ +0.39pp | 2024-02-14 |
| Nos. of above persons | 4.70% | 6.2M | ▼ -4.09pp | 2024-09-09 |
内部人交易
Net 90d: +$0 · buys $0 / sells $0时间范围:
类型:
身份:
| 内部人 | 身份 | 类型 | ||||
|---|---|---|---|---|---|---|
| 2026-02-10 | Ltd. Deep Track Biotechnology Master Fund | 10% Owner | Disposed (U) | 15.73M | — | — |
| 2026-02-10 | Metzinger Joseph Anthony | VP, Chief Accounting Officer | Disposed (U) | 7.1K | — | — |
| 2026-02-10 | Ryan Spencer | CEO and Director | Disposed (U) | 379.6K | — | — |
| 2026-02-10 | Ryan Spencer | CEO and Director | Grant | 165.0K | — | — |
| 2026-02-10 | Ryan Spencer | CEO and Director | Disposition | 165.0K | — | — |
| 2026-02-10 | Ryan Spencer | CEO and Director | Grant | 136.0K | — | — |
| 2026-02-10 | Ryan Spencer | CEO and Director | Disposition | 136.0K | — | — |
| 2026-02-10 | Slebir John L | SVP General Counsel | Disposed (U) | 69.6K | — | — |
| 2026-02-10 | Slebir John L | SVP General Counsel | Grant | 50.0K | — | — |
| 2026-02-10 | Slebir John L | SVP General Counsel | Disposition | 50.0K | — | — |
1–10 of 31
第 1 页 / 共 4 页